JPWO2020243519A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243519A5 JPWO2020243519A5 JP2021570361A JP2021570361A JPWO2020243519A5 JP WO2020243519 A5 JPWO2020243519 A5 JP WO2020243519A5 JP 2021570361 A JP2021570361 A JP 2021570361A JP 2021570361 A JP2021570361 A JP 2021570361A JP WO2020243519 A5 JPWO2020243519 A5 JP WO2020243519A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- optionally substituted
- ring
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 123
- 229910052757 nitrogen Inorganic materials 0.000 claims description 95
- 125000005842 heteroatom Chemical group 0.000 claims description 78
- 125000006413 ring segment Chemical group 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 46
- 125000005843 halogen group Chemical group 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 125000003427 indacenyl group Chemical group 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- OHKPZFLGCGOJEJ-UHFFFAOYSA-N spiro[1,3-dihydroindene-2,1'-cyclopropane] Chemical compound C1CC11CC2=CC=CC=C2C1 OHKPZFLGCGOJEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- -1 C(=O)OH Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854288P | 2019-05-29 | 2019-05-29 | |
| US62/854,288 | 2019-05-29 | ||
| PCT/US2020/035249 WO2020243519A1 (en) | 2019-05-29 | 2020-05-29 | Compounds and compositions for treating conditions associated with sting activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535743A JP2022535743A (ja) | 2022-08-10 |
| JPWO2020243519A5 true JPWO2020243519A5 (https=) | 2023-06-01 |
| JP2022535743A5 JP2022535743A5 (https=) | 2023-06-01 |
Family
ID=71787083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570361A Pending JP2022535743A (ja) | 2019-05-29 | 2020-05-29 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220227760A1 (https=) |
| EP (1) | EP3976584A1 (https=) |
| JP (1) | JP2022535743A (https=) |
| MA (1) | MA56047A (https=) |
| WO (1) | WO2020243519A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823036B (zh) | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN117222634A (zh) * | 2020-12-16 | 2023-12-12 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2022133098A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CN102206216B (zh) * | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| CN102812023A (zh) * | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| US9763922B2 (en) * | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN113226323B (zh) * | 2018-11-15 | 2024-12-31 | 法国古士塔柏罗斯学院 | 马德辛衍生化合物、组合物及其用于治疗癌症的用途 |
| EP3883651A1 (en) * | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
-
2020
- 2020-05-29 US US17/610,570 patent/US20220227760A1/en not_active Abandoned
- 2020-05-29 MA MA056047A patent/MA56047A/fr unknown
- 2020-05-29 EP EP20746384.5A patent/EP3976584A1/en not_active Withdrawn
- 2020-05-29 JP JP2021570361A patent/JP2022535743A/ja active Pending
- 2020-05-29 WO PCT/US2020/035249 patent/WO2020243519A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| US9850258B2 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | |
| RU2003110577A (ru) | Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами | |
| JP2020506951A5 (https=) | ||
| EA200400830A1 (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ОТНОСЯЩИЕСЯ К A2b-СЕЛЕКТИВНЫМ АНТАГОНИСТАМ, ИХ СИНТЕЗ И ПРИМЕНЕНИЕ | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2010506854A5 (https=) | ||
| JPWO2020243519A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| RU2004126671A (ru) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| JP2017519754A5 (https=) | ||
| KR20230012535A (ko) | Enpp1 조절제 및 이의 용도 | |
| JPH0725864A (ja) | 化学療法剤としての１，２，４−ジチアゾリウム塩類の使用 | |
| JPWO2021138434A5 (https=) | ||
| RU2004116473A (ru) | Производные пиридина в качестве блокаторов подтипа nmda- рецепторов | |
| RU2008115499A (ru) | Новые производные аминокиламидов в качестве антагонистов лигандов рецепторов ccr3 | |
| JP2021514399A5 (https=) | ||
| JP5922157B2 (ja) | （−）−フペルジンａの工程及び関連組成物並びに治療法 | |
| JPWO2019164947A5 (https=) | ||
| JP2021517160A (ja) | Ｆｍｓ様チロシンキナーゼ阻害剤 | |
| CN121399105A (zh) | 杂芳族dhodh抑制剂 | |
| RU2020141171A (ru) | Соединения для лечения рака поджелудочной железы |